Wiese, Maria

[["dc.bibliographiccitation.firstpage","1"],["dc.bibliographiccitation.journal","European Journal of Cancer"],["dc.bibliographiccitation.lastpage","8"],["dc.bibliographiccitation.volume","81"],["dc.contributor.author","Karremann, Michael"],["dc.contributor.author","Krämer, Nadja"],["dc.contributor.author","Hoffmann, Marion"],["dc.contributor.author","Wiese, Maria"],["dc.contributor.author","Beilken, Andreas"],["dc.contributor.author","Corbacioglu, Selim"],["dc.contributor.author","Dilloo, Dagmar"],["dc.contributor.author","Hernaiz Driever, Pablo"],["dc.contributor.author","Scheurlen, Wolfram"],["dc.contributor.author","Kulozik, Andreas"],["dc.contributor.author","Gielen, Gerrit H."],["dc.contributor.author","von Bueren, André"],["dc.contributor.author","Dürken, Matthias"],["dc.contributor.author","Kramm, Christof M."],["dc.date.accessioned","2018-10-10T07:47:12Z"],["dc.date.available","2018-10-10T07:47:12Z"],["dc.date.issued","2017"],["dc.description.abstract","Temozolomide (TMZ) is widely used in high-grade glioma (HGG). There is a major concern of treatment-induced secondary haematological malignancies (SHMs). Due to the poor overall survival of HGG patients, the true incidence is yet elusive. Thus, the aim of this study was to determine the risk of SHMs following TMZ in paediatric HGG. We analysed 487 patients from the HIT-HGG database of the German-speaking Society of Pediatric Oncology and Hematology with follow up beyond 1 year. The incidence of SHM was 7.7 ± 3.2% at 10 years. No SHM occurred in 194 patients after first-line TMZ therapy, but four out of 131 patients treated with TMZ for relapse following first-line multiagent chemotherapy experienced SHM (20% at 10 years; p = 0.041). SHMs occurred in two out of 162 patients who underwent multiagent chemotherapy without TMZ (4.1% at 10 years). Gender, patient age and acute haematological toxicity during treatment did not affect the incidence of SHMs. Data of our cohort do not indicate an increased risk of SHM following TMZ treatment when compared to previous chemotherapy regimen. However, if TMZ is administered as a second-line treatment following conventional chemotherapy regimen, the risk might be disproportionately increasing."],["dc.fs.pkfprnr","58469"],["dc.identifier.doi","10.1016/j.ejca.2017.04.023"],["dc.identifier.fs","633320"],["dc.identifier.pmid","28586748"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/15921"],["dc.language.iso","en"],["dc.notes.status","final"],["dc.relation.eissn","1879-0852"],["dc.title","Haematological malignancies following temozolomide treatment for paediatric high-grade glioma"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","123"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Neuro-Oncology"],["dc.bibliographiccitation.lastpage","131"],["dc.bibliographiccitation.volume","20"],["dc.contributor.author","Karremann, Michael"],["dc.contributor.author","Gielen, Gerrit H"],["dc.contributor.author","Hoffmann, Marion"],["dc.contributor.author","Wiese, Maria"],["dc.contributor.author","Colditz, Niclas"],["dc.contributor.author","Warmuth-Metz, Monika"],["dc.contributor.author","Bison, Brigitte"],["dc.contributor.author","Claviez, Alexander"],["dc.contributor.author","van Vuurden, Dannis G"],["dc.contributor.author","von Bueren, André O"],["dc.contributor.author","Gessi, Marco"],["dc.contributor.author","Kühnle, Ingrid"],["dc.contributor.author","Hans, Volkmar H"],["dc.contributor.author","Benesch, Martin"],["dc.contributor.author","Sturm, Dominik"],["dc.contributor.author","Kortmann, Rolf-Dieter"],["dc.contributor.author","Waha, Andreas"],["dc.contributor.author","Pietsch, Torsten"],["dc.contributor.author","Kramm, Christof M"],["dc.date.accessioned","2020-12-10T18:19:37Z"],["dc.date.available","2020-12-10T18:19:37Z"],["dc.date.issued","2017"],["dc.identifier.doi","10.1093/neuonc/nox149"],["dc.identifier.eissn","1523-5866"],["dc.identifier.issn","1522-8517"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/75312"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Neuro-Oncology Advances"],["dc.bibliographiccitation.volume","3"],["dc.contributor.author","Baugh, Joshua N"],["dc.contributor.author","Gielen, Gerrit H"],["dc.contributor.author","van Vuurden, Dannis G"],["dc.contributor.author","Veldhuijzen van Zanten, Sophie E M"],["dc.contributor.author","Hargrave, Darren"],["dc.contributor.author","Massimino, Maura"],["dc.contributor.author","Biassoni, Veronica"],["dc.contributor.author","Morales la Madrid, Andres"],["dc.contributor.author","Karremann, Michael"],["dc.contributor.author","Wiese, Maria"],["dc.contributor.author","Kramm, Christof M"],["dc.date.accessioned","2021-12-01T09:23:15Z"],["dc.date.available","2021-12-01T09:23:15Z"],["dc.date.issued","2021"],["dc.description.abstract","Abstract Background Pediatric neuro-oncology was profoundly changed in the wake of the 2016 revision of the WHO Classification of Tumors of the Central Nervous System. Practitioners were challenged to quickly adapt to a system of tumor classification redefined by molecular diagnostics. Methods We designed a 22-question survey studying the impact of the revised WHO classification on pediatric high-grade glioma. The survey collected basic demographics, general attitudes, issues encountered, and opinions on pediatric subtypes. Participant answers were analyzed along socioeconomic lines utilizing the human development index (HDI) of the United Nations and membership in the group of seven (G7) world economic forum. Results Four hundred and sixty-five participants from 53 countries were included, 187 pediatric neurooncologists (40%), 160 neuropathologists (34%), and 118 other experts (26%). When asked about pediatric high-grade glioma entities, participants from very high development countries preferred treating a patient based on genetic findings. Participants from high and medium development countries indicated using traditional histology and tumor location as mainstays for therapeutic decisions. Non-G7 countries tended to regard the introduction of molecularly characterized tumor entities as a problem for daily routine due to lack of resources. Conclusions Our findings demonstrate an overall greater reliance and favorability to molecular diagnostics among very high development countries. A disparity in resources and access to molecular diagnostics has left some centers unable to classify pediatric high-grade glioma per the WHO classification. The forthcoming edition should strain to abate disparities in molecular diagnostic availability and work toward universal adaptation."],["dc.description.abstract","Abstract Background Pediatric neuro-oncology was profoundly changed in the wake of the 2016 revision of the WHO Classification of Tumors of the Central Nervous System. Practitioners were challenged to quickly adapt to a system of tumor classification redefined by molecular diagnostics. Methods We designed a 22-question survey studying the impact of the revised WHO classification on pediatric high-grade glioma. The survey collected basic demographics, general attitudes, issues encountered, and opinions on pediatric subtypes. Participant answers were analyzed along socioeconomic lines utilizing the human development index (HDI) of the United Nations and membership in the group of seven (G7) world economic forum. Results Four hundred and sixty-five participants from 53 countries were included, 187 pediatric neurooncologists (40%), 160 neuropathologists (34%), and 118 other experts (26%). When asked about pediatric high-grade glioma entities, participants from very high development countries preferred treating a patient based on genetic findings. Participants from high and medium development countries indicated using traditional histology and tumor location as mainstays for therapeutic decisions. Non-G7 countries tended to regard the introduction of molecularly characterized tumor entities as a problem for daily routine due to lack of resources. Conclusions Our findings demonstrate an overall greater reliance and favorability to molecular diagnostics among very high development countries. A disparity in resources and access to molecular diagnostics has left some centers unable to classify pediatric high-grade glioma per the WHO classification. The forthcoming edition should strain to abate disparities in molecular diagnostic availability and work toward universal adaptation."],["dc.identifier.doi","10.1093/noajnl/vdab113"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/94599"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-478"],["dc.relation.eissn","2632-2498"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0/"],["dc.title","Transitioning to molecular diagnostics in pediatric high-grade glioma: experiences with the 2016 WHO classification of CNS tumors"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]